Pierre Fabre Partners With Piqur

Swiss pharmaceutical company Piqur Therapeutics and French pharmaceutical group Pierre Fabre have signed a collaboration agreement for the development of Piqur’s lead compound PQR309, a PI3K/mTOR inhibitor, in dermato-oncology. Piqur and Pierre Fabre’s R&D teams will work together on the evaluation and development of dermatological formulations of PQR309 across multiple therapeutic indications.

Following the first stage of the collaboration, Pierre Fabre will have the option to enter into exclusive negotiations to license global rights for the program in selected skin cancer conditions. Terms and conditions of the collaboration were undisclosed.

“The collaboration with Pierre Fabre, a worldwide leader in dermatology, is an important milestone for Piqur, validating its potential to bring novel solutions to patients for the treatment of dermato-oncology diseases with unmet medical needs,” said Hervé Girsault, chief business officer of Piqur.

“We are looking forward to working with Piqur as part of our commitment to external innovation. This collaboration with Piqur marks an additional milestone in our partnering strategy. Combining our capabilities will accelerate the drug discovery process and bringing forward transformative therapies for patients,” said Laurent Audoly, head of research & development at Pierre Fabre Pharmaceuticals.